Finerenone-induced reduction in albuminuria in patients with CKD, diabetes
November 07, 2021
1 minute watch
Source / Disclosures
Bakris GL, et al. SA-OR21 paper. Presented at: ASN Kidney Week; 4-7 Nov 2021 (virtual meeting).
George L. Bakris, MD, a professor of medicine and director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about a new subgroup analysis of the FIGARO-DKD trial.
Researchers presented kidney side results from FIGARO-DKD, a randomized, double-blind, placebo-controlled Phase 3 trial, to ASN Kidney Week. They found that finerenone induced a marked reduction in albuminuria in patients with stage 1 to 4 chronic kidney disease and type 2 diabetes.
âUltimately, there was a 23% reduction in the risk of doubling creatinine. Second, and I think the most important, there was a 20% reduction in dialysis time. As a result, we reduced dialysis time by 20% in those people who did not necessarily have advanced kidney disease. They had eGFR in the 60s with microalbuminuria, âhe said.